CSL’s garadacimab, under the brand name Andembry, has been approved in the U.K. and Australia for the routine prevention of swelling attacks in adults and adolescents with hereditary angioedema (HAE), ages 12 and older. In Australia, the therapy is intended for HAE patients with deficiency or dysfunction of…
News
Pharvaris plans a trial of deucrictibant to treat acquired angioedema this year, following promising data showing the experimental oral small molecule helped to stop or prevent swelling attacks in three patients. The company has been testing deucrictibant in a pair of Phase 3 trials, CHAPTER-3 (NCT06669754)…
Intellia Therapeutics is planning to submit an application requesting the approval of NTLA-2002, its gene-editing therapy for hereditary angioedema (HAE), to U.S. regulators in late 2026. The company recently announced it would be discontinuing programs for other diseases, as well as reducing its workforce, to focus efforts…
Takhzyro (lanadelumab), an injectable medication used to prevent hereditary angioedema (HAE) attacks, is highly effective at reducing the frequency of these episodes and increasing the proportion of patients who remain attack-free, a study into its real-world use reports. Researchers evaluated Takhzyro’s use in the clinic among HAE patients…
Delaying on-demand treatment of hereditary angioedema (HAE) swelling attacks increases their severity and duration, and its symptoms are also more likely to spread to other parts of the body, according to a study that also found about 79% of patients reported treatment-related anxiety, which was associated with delaying…
Despite being on prophylatic, or preventive, treatment, people with hereditary angioedema (HAE) report similar struggles in managing and recovering from acute attacks to those using on-demand therapy alone, a new survey study in the U.S. has revealed. The researchers noted that anxiety levels among patients when anticipating the use…
Diet and physical activity may trigger swelling attacks in people with hereditary angioedema (HAE), according to a patient survey study conducted in Germany. About a third of patients surveyed experienced swelling attacks related to the consumption of certain foods, including fruits, vegetables, bread, or dairy products, while some…
Throughout 2024, Angioedema News brought our readers all the latest news and updates on clinical research and scientific advances related to the rare disease. Here are this year’s top 10 most-read articles on angioedema — many related to the prevention and treatment of swelling, the hallmark of the…
Switching from long-term androgen treatment to Takhzyro (lanadelumab) successfully prevented swelling attacks and reduced cardiovascular risk in a man with hereditary angioedema (HAE) type 1, according to a report from Italy. The man had undergone two kidney transplants and was on immunosuppressant medications for several years. According to…
A European Medicines Agency (EMA) committee has recommended that the antibody-based therapy garadacimab be approved as a once-monthly preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE) ages 12 and older. The positive opinion from the EMA’s Committee for Medicinal Products…
Recent Posts
- Rare Disease Week is an opportunity to show that rare is not invisible
- Case highlights rare, life-threatening reaction to common antibiotic
- Dawnzera wins approval in EU as preventive treatment for HAE
- Preparing for an internet or power outage is crucial with angioedema
- A caregiver’s role when facing the ‘boss levels’ of HAE